EMEA-001860-PIP03-16-M07

Table of contents

Key facts

Invented name
Emgality
Active substance
Galcanezumab
Therapeutic area
Neurology
Decision number
P/0142/2022
PIP number
EMEA-001860-PIP03-16-M07
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of migraine headaches
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Eli Lilly & Company Limited

E-mail: eu_paediatric@lilly.com 
Tel. +44 (0)1276 483000

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating